The acquisition of global rights to NJO from Sanofi is expected to contribute positively to EBITDA from 2025 onwards. Recordati SpA (RICFY) reported a robust free cash flow of 434.3 million euros, up ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

On the way, it acquired Sanofi India's vaccine portfolio, which has helped it deliver double-digit domestic growth in the ...

Revenue for Emcure Pharma Q2 rose by over 20%, totaling ₹2,002 Crore, driven by strong performance across segments.

In an exclusive interview with Nigeria Health Watch, Dr Mukhtar outlined the Executive Order's two-year validity, and its transformative provisions. Central to this includes the removal of tariffs, ...

Sanofi Korea Corporation (hereinafter referred to as Sanofi) successfully concluded the RSV story contest\ for parents who ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...

Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the qu ...